Halda Therapeutics

Laboratory
Dec 29, 2025

J&J completes $3.05B Halda Therapeutics acquisition

The addition of the Connecticut biotech expands Johnson & Johnson's oncology pipeline in prostate cancer and solid tumor treatments.

The New York Stock Exchange welcomed Johnson & Johnson to ring the Opening Bell on Dec. 5, 2023, as part of the company's celebration of the 80th anniversary of its "Our Credo." J&J Chairman and CEO Joaquin Duato, as well as several J&J employees, joined Lynn Martin, NYSE president, for the honor.
Nov 17, 2025

J&J to acquire Connecticut biotech in $3.05B oncology deal

Johnson & Johnson's latest target, Halda Therapeutics, will add prostate cancer therapy HLD-0915 along with other early-stage assets.